Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Assets (2016 - 2026)

Myriad Genetics has reported Other Non-Current Assets over the past 14 years, most recently at $5.6 million for Q4 2025.

  • Quarterly Other Non-Current Assets fell 34.12% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 34.12% year-over-year, with the annual reading at $5.6 million for FY2025, 34.12% down from the prior year.
  • Other Non-Current Assets was $5.6 million for Q4 2025 at Myriad Genetics, down from $6.6 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $22.1 million in Q2 2023 and troughed at $3.6 million in Q1 2021.
  • The 5-year median for Other Non-Current Assets is $8.4 million (2021), against an average of $10.7 million.
  • Year-over-year, Other Non-Current Assets skyrocketed 566.67% in 2021 and then plummeted 60.0% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $8.3 million in 2021, then skyrocketed by 86.75% to $15.5 million in 2022, then dropped by 0.65% to $15.4 million in 2023, then tumbled by 44.81% to $8.5 million in 2024, then crashed by 34.12% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Non-Current Assets are $5.6 million (Q4 2025), $6.6 million (Q3 2025), and $7.1 million (Q2 2025).